Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arbutus Biopharma Corp

ABUS
Current price
2.03 USD -0.01 USD (-0.49%)
Last closed 2.05 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 313 589 664 USD
Yield for 12 month -18.15 %
Week
Month
Year
ABUS
21.11.2021 - 28.11.2021

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974

Analytics

WallStreet Target Price

4.5 USD

P/E ratio

Dividend Yield

Current Year

+39 019 000 USD

Last Year

+10 988 000 USD

Current Quarter

+4 658 000 USD

Last Quarter

+4 651 000 USD

Current Year

+39 019 000 USD

Last Year

+10 988 000 USD

Current Quarter

+4 658 000 USD

Last Quarter

+4 651 000 USD

Key Figures ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -77 115 000 USD
Operating Margin TTM -458.42 %
PE Ratio
Return On Assets TTM -27.06 %
PEG Ratio
Return On Equity TTM -56.99 %
Wall Street Target Price 4.5 USD
Revenue TTM 22 241 000 USD
Book Value 0.71 USD
Revenue Per Share TTM 0.14 USD
Dividend Share
Quarterly Revenue Growth YOY -21.7 %
Dividend Yield
Gross Profit TTM -45 389 000 USD
Earnings Share -0.46 USD
Diluted Eps TTM -0.46 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ABUS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 04.11.2010
Dividend Date

Stock Valuation ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.6703
Price Sales TTM 11.6763
Enterprise Value EBITDA -4.5333
Price Book MRQ 2.8064

Financials ABUS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ABUS

For 52 weeks

1.69 USD 3.15 USD
50 Day MA 1.87 USD
Shares Short Prior Month 5 773 478
200 Day MA 2.34 USD
Short Ratio 12.13
Shares Short 6 311 590
Short Percent 5.01 %